Search company, investor...

Ancora Pharmaceuticals

ancorapharma.com

Founded Year

2001

Stage

Unattributed VC - II | Alive

Total Raised

$1.6M

Last Raised

$800K | 15 yrs ago

About Ancora Pharmaceuticals

Ancora Pharmaceuticals aims to enable synthetic carbohydrate-based product discovery and development utilizing its carbohydrate synthesis capability, which is based on technology originally developed at the Massachusetts Institute of Technology (M.I.T.). The company is applying its synthesis technology both to internal drug development programs and strategic collaborations within the pharmaceutical and biotechnology sector.

Headquarters Location

1-B Gill Street

Woburn, Massachusetts, 01801,

United States

781-305-3332

Missing: Ancora Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Ancora Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Ancora Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ancora Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Ancora Pharmaceuticals Patents

Ancora Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/27/2011

5/6/2014

Monoclonal antibodies, Immune system, Immunology, EC 2.4.1, Clusters of differentiation

Grant

Application Date

4/27/2011

Grant Date

5/6/2014

Title

Related Topics

Monoclonal antibodies, Immune system, Immunology, EC 2.4.1, Clusters of differentiation

Status

Grant

Latest Ancora Pharmaceuticals News

CordenPharma Acquires Ancora Pharmaceuticals’ Technology

Nov 12, 2013

Ancora Pharmaceuticals Inc. a leading carbohydrate synthesis company CordenPharma International US Inc. an expert contract manufacturing organization CMO and Harris & Harris Group Inc. NASDAQ TINY an investor in transformati...

Ancora Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Ancora Pharmaceuticals founded?

    Ancora Pharmaceuticals was founded in 2001.

  • Where is Ancora Pharmaceuticals's headquarters?

    Ancora Pharmaceuticals's headquarters is located at 1-B Gill Street, Woburn.

  • What is Ancora Pharmaceuticals's latest funding round?

    Ancora Pharmaceuticals's latest funding round is Unattributed VC - II.

  • How much did Ancora Pharmaceuticals raise?

    Ancora Pharmaceuticals raised a total of $1.6M.

  • Who are the investors of Ancora Pharmaceuticals?

    Investors of Ancora Pharmaceuticals include 180 Degree Capital.

  • Who are Ancora Pharmaceuticals's competitors?

    Competitors of Ancora Pharmaceuticals include Tetraphase Pharmaceuticals, Stemina Biomarker Discovery, Actinobac Biomed, Viamet Pharmaceuticals, CoLucid Pharmaceuticals and 11 more.

Compare Ancora Pharmaceuticals to Competitors

A
Affinium Pharmaceuticals

Affinium Pharmaceuticals is a specialty pharmaceutical company developing a class of antibiotics that target the bacterial fatty acid synthesis (FASII) pathway. AFN-1252, the company's lead clinical compound, is a highly-potent, small molecule antibiotic for both oral and IV treatment of staphylococcal infections, including MRSA and all other drug-resistant strains.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

L
Locus Pharmaceuticals

Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.

U
Ulysses Pharmaceuticals

Ulysses Pharmaceuticals is dedicated to the discovery and development of safe antimicrobial agents for the treatment of severe and recurrent infections occurring in humans. The Company intends to become an industry leader in the antiinfective field through the development of new antibiotics including some acting as Trojan Horses that take advantage of essential microbial transport systems to specifically enter targeted pathogens. Ulysses concentrates on the development of advanced hit and lead compounds with promising features and characteristics that are indicative of potent antibacterial agents with potential for strong market penetration.

R
Ren Pharmaceuticals

Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals is interested in building collaborative research programs with academic institutions. Ren Pharmaceuticals is developing data and useful reagents (e.g. antibodies, recombinant proteins) for studying the biology of renalase. We are interested in in-licensing and developing products that leverage our core strengths and complement our existing portfolio. Products with applications in kidney disease and associative diseases (e.g. cardio-renal diseases) are key areas of interest.

A
Advent Pharmaceuticals

Advent Pharmaceuticals is a specialty pharmaceutical company focused on developing inhaled drug products using a dry powder inhalation delivery system. The products are mostly used for the treatment of asthma and other respiratory diseases.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.